Chun-Fang Hao

Current evidence and treatment strategies of CDK4/6 inhibitors in HR+/HER2- young breast cancer

Breast cancer (BC) in young women is associated with more aggressive tumor biology, increased risk of recurrence, as well as worse prognosis, with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) subtype accounting for 54–61% of cases. While cyclin-dependent kinase 4/6 inhibi...